A Study of LY3041658 in Adults With Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT04493502

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04493502. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Study identification

NCT ID: NCT04493502
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

Hidradenitis Suppurativa

Interventions

Placebo Drug
LY3041658 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 26, 2020 (Actual)
Primary completion: Mar 15, 2022 (Actual)
Completion: Oct 13, 2022 (Actual)
Last update posted: Apr 28, 2023

2020 – 2022

United States locations

U.S. sites: 15
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
Northwest Arkansas Clinical Trials Center	Rogers	Arkansas	72758	—
First OC Dermatology	Fountain Valley	California	92708	—
Dermatology Research Associates	Los Angeles	California	90045	—
Skin Care Research, Inc	Hollywood	Florida	33021	—
Nova Clinical Research, LLC	Miami	Florida	33125	—
ForCare Clinical Research	Tampa	Florida	33613-1244	—
Marietta Dermatology Clinical Research	Marietta	Georgia	30060	—
Advanced Medical Research	Sandy Springs	Georgia	30328	—
Allcutis Research, Inc.	Beverly	Massachusetts	01915	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Washington University School of Medicine	St Louis	Missouri	63110	—
ALLCUTIS Research	Portsmouth	New Hampshire	03801	—
Duke University Medical Center	Durham	North Carolina	27710	—
UC Physicians Office Dermatology	Cincinnati	Ohio	45267	—
University Hospitals Case Medical Center	Cleveland	Ohio	44106	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04493502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 28, 2023 · Synced Nov 12, 2026